Stemolecule™ PD0325901

Catalog Size Price Quantity
04-0006 2 mg $203.00
04-0006-10 10 mg $799.00
Add To Cart
Order Offline
T: 877.228.9783
F: 617.812.5900
E: orders@stemgent.com

Bulk Orders? Call 877-303-2654 or fill out this form

04 0006 Figure 1

Product Overview

PD0325901 is a small molecule targeting mitogen-activated protein kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. PD0325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation1,2. Along with the ALK5 inhibitor SB431542, PD0325901 has also been shown to increase the efficiency of reprogramming human primary fibroblasts into induced pluripotent stem (iPS) cells3.

 
Also available: Stemolecule™ PD0325901 in Solution (04-0006-02)
 

Stemgent conveniently provides all the components comprising the 5i/L/A media supplment necessary to support naive pluripotent stem cell applications.

5i (inhibitors):

L: Stemfactor™ LIF, Human Recombinant (03-0016), and

A: Stemfactor™ Activin A, Human Recombinant (03-0001)

Product Specifications

Size

2 mg (Cat. No. 04-0006)
10 mg (Cat. No. 04-0006-10)

Chemical Name

N-​[(2R)-​2,​3-​dihydroxypropoxy]-​3,​4-​difluoro-​2-​[(2-​fluoro-​4-​iodophenyl)amino]-​benzamide

Chemical Formula

C16H14F3IN2O4 

Molecular Weight

482.19 

CAS Number

391210-10-9

Purity

Greater than 97% by HPLC analysis

Formulation

Pale purple solid

Solubility

Reconstitute in DMSO to the desired concentration. For reconstitution instructions please reference product specifications sheet.

Storage and Stability

Store powder at 4°C protected from light. Following reconstitution, store aliquots at -20°C. Stock solutions are stable for 6 months when stored as directed. 

Quality Control

The purity of PD0325901 was determined by HPLC analysis. The accurate mass was determined by mass spectrometry. No acute cytotoxicity was observed in mouse embryonic stem cells following a 6 hour exposure to 1 nM - 100 µM of PD0325901.

References

  1. Bain, J., Plater, L., Elliott, M., Hastie, C.J., McLauchlan, H., Klevernic, I., Arthur, J.S., Alessi, D.R., and Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update.Biochem. J. 408: 297-315.
  2. Sebolt-Leopold, J.S. and Herrera, R. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947.
  3. Lin, T., Ambasudhan, R., Yuan, X., Li, W., Hilcove, S., Abujarour, R., Lin, X., Hahm, H.S., Hao, E., Hayek, A., and Ding, S. (2009) A chemical platform for improved induction of human iPSCs. Nat Methods 6: 805-808.

Additional Publications

Customers Also Purchased

CHIR99021
04-0004
2 mg $203.00
Oct4-GFP MEF (P2)
08-0028
1.0 x 106 cells/vial $499.00
LDN-193189
04-0074
2 mg $203.00
PD0325901 in Solution
04-0006-02
2 mg (10 mM) $239.00


Stemgent Comments and Reviews (0)

No comments or reviews yet. Be the first to leave a review.

Add a Comment

You must log-in or register as a Stemgent member to submit a comment.

You are fully responsible for the content you post. We encourage collaboration and helpful reviews among scientists and will use this feature to conduct helpful reviews of our products. Content that includes profanity, personal attacks or antisocial behavior (such as "spamming" or "trolling"), or other inappropriate content or material will be removed. We reserve the right to block any user who violates our terms of use, including removing all content posted by that user.